This is a first-in-human study of VA111913 TS, a new chemical entity being developed for the
treatment of dysmenorrhea. This study is designed to investigate determine the safety,
tolerability and pharmacokinetics of VA111913 TS after single and multiple doses in healthy
non-pregnant female volunteers of child bearing age.